Brief: FDA Approves New Leqembi Subcutaneous Dosing Regimen For Alzheimer's
13/07/2026 19:12
BRIEF-FDA Approves New Leqembi Subcutaneous Dosing Regimen For Alzheimer's July 13 (Reuters) - FDA:
APPROVES NEW STARTING DOSAGE REGIMEN FOR LEQEMBI SUBCUTANEOUS FORMULATION FOR ALZHEIMER’S DISEASE TREATMENT
Further company coverage: BIIB.O
Recent news on Biogen
See all newsUS RESEARCH ROUNDUP-Autodesk, Metlife, Rollins
Brief: Biogen Says DZP Plus Soc Meets Primary Endpoint Of BICLA Response At Week 48
Brief: Biogen Provides Update On Private Payer Coverage For Zurzuvae™ (Zuranolone)
US RESEARCH ROUNDUP-Eli Lilly, General Dynamics, S&P Global
US RESEARCH ROUNDUP-Baker Hughes, Brinker International, GE Vernova